Brain Tumor Diagnosis And Therapeutics Market is accounted approximate USD 1.4 billion in 2020 and it is expected to reach approximate USD 4.5 billion by 2030 with a CAGR of 12.5% during forecast period. A brain tumor is a mass, of abnormal cells in the brain of human body. The skull which encloses the brain is very rigid and growth inside such a restricted space causes various problems. Moreover, brain tumors can be cancerous or non-cancerous. Additionally brain tumor can cause brain damage, and it can be life threatening. Brain tumor can occur in any age group. Neurologists treat the tumor on the basis of tumor type, tumor location, and tumor size.

Market Segmentation:

On the basis of type, the brain tumor diagnostics and therapeutics market is bifurcated into two types that are primary brain tumor and secondary brain tumor. Based on diagnosis it is segmented into CT scan, MRI, PET-CT scan, molecular testing, EEG, tissue testing, and others. On the basis of therapeutics it is classified into surgery, radiation therapy, targeted therapy, chemotherapy, and immunotherapy. Based on region it is segmented into North America, Asia Pacific, Europe, and ROW.

Market Dynamics and Factors:

Rising prevalence of brain cancer and growing geriatric population are anticipated to nurture market growth for brain tumor diagnosis and therapeutics. In addition, increasing investment in R&D by the public and private sector for innovating new therapeutics are driving the market. Additionally, increase in investment by government and independent organizations such as the WHO, American brain tumor association, and International brain tumor alliances for supporting of availability of treatment and conducting research on novel cure for the disease  is driving the market growth. In addition, evolving diagnostic and radiology services such as Sodium magnetic resonance imaging, chemical exchange saturation transfer, and positron emission tomography are driving the market growth. Moreover, the development of innovative therapeutics and rising awareness about diagnosis among the consumers can be opportunity for the market. However, high cost involved in the diagnosis and treatments of brain tumor is anticipated to hinder the growth of market.

Geographic Analysis:

North America is dominating the market and is anticipated to maintain same trend during the forecast period. According to research report, in 2017 region held approximate 47% of the global market for brain tumor diagnosis and therapeutics. The U.S. held approximate 88% of the regional market in 2017. The rapid increase in the population suffering from brain tumors in the region is anticipated to market growth. Asia Pacific is anticipated to show fastest growth and expected to maintain same trend during forecast period. Increase in the prevalence of brain tumors, introduction of various technologies and therapies in the region are driving the market growth.

Competitive Scenario:

Some of the key players in global brain tumor diagnosis and therapeutics are Pfizer Inc., Merck & Co. Inc., Hitachi Medical Corporation, Toshiba medical system corporation, Shimadzu Corporation, Siemens healthineers, AstraZeneca Plc, Philips healthcare. 

Brain Tumor Diagnostics and Therapeutics Market Report Scope